Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Clinical trial NCT05616390 · UNKNOWN
Trial details
- NCT number
- NCT05616390
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-09
- Primary completion
- 2023-11-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.